Chart Thread, page-1056

I picked up more today, no longer free carrying.

I may have pulled the trigger too early, but I placed the order at $3.20 ages ago and tbh completely forgot about it.

But I'm glad I did. As we saw the other day this company is very prone to having unexpected announcements and partnerships. With the breadth of the products they offer there are many potential commercialisation and research opportunities that could pop up unexpectedly.

The type 3 diabetes test is neat, I wasn't too excited about it though. But if something exciting drops it'll be good to be holding, we all saw what happened earlier this year.

There's two major announcements that we are due soon. The first one is the Bard1 ovarian cancer independent evaluation. It was due to be completed Q1 CY2021 so we could get an announcement on the results any time now (fingers crossed they're good).

This could be a huge one, most people know how devastating ovarian cancer is and how difficult it is to diagnose.

The second is the announcement of commercial launch of the EXO-NET product for research purposes which, again, could be huge as it will be revenue generating.

So I'm gonna sit on this and wait.

GLTAH